Objectives: To determine if a low Health Assessment Questionnaire Disability Index (HAQ-DI) score predicts subsequent improvement over the next one to two years in clinical practice and if a low HAQ is predictive of improvement in early, late, diffuse and limited SSc subsets.
Methods: HAQs collected at one site annually were used to determine serial relationships in low baseline HAQ and improvement in overall status over the following one to two years. Data were divided into early (< or =3 years) and late, and then further into limited and diffuse SSc subgroups. We verified our results in the Canadian Scleroderma Research Group (CSRG) database.
Results: 120 SSc patients had a baseline HAQ-DI of 0.97+/-0.07 (SEM). Low HAQs predicted improvement in overall HAQ at one and two years, but was not statistically significant in predicting physician improvement rating. However, improving HAQs were associated with improvement in physician assessment (better vs. same vs. worse) for overall SSc (p=0.005), early diffuse SSc (p=0.008), overall limited SSc (p=0.02) and late limited SSc (p=0.03) at 1 year (but not at 2 years). The relationship was similar for severity of disease where changes in damage were related to changes in HAQ only over the first year for all 4 subgroups.
Conclusion: The HAQ is a useful 'marker' of change in status in clinical practice, where an improved HAQ is associated with improved physician global assessment. The relationship is only helpful for an interval of one year. Low HAQ did not predict subsequent improvement by physician rating in SSc patients.
Download full-text PDF |
Source |
---|
Pharmacoeconomics
January 2025
Belgian Health Care Knowledge Centre, Brussels, Belgium.
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data.
View Article and Find Full Text PDFCurr Obes Rep
January 2025
Metabolism and Body Composition, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
Background: Recent technological advances have introduced novel methods for measuring body composition, each with unique benefits and limitations. The choice of method often depends on the trade-offs between accuracy, cost, participant burden, and the ability to measure specific body composition compartments.
Objective: To review the considerations of cost, accuracy, portability, and participant burden in reference and emerging body composition assessment methods, and to evaluate their clinical applicability.
J Assist Reprod Genet
January 2025
Brussels IVF, Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Purpose: This survey aimed to assess the public's knowledge and opinions on oocyte donation (OD) among a large, unselected cohort of young Belgian women, and to explore aspects that could be enhanced to promote future OD programs.
Methods: We conducted a quantitative, epidemiological, cross-sectional web-based survey from February 2023 to April 2023. A private questionnaire was distributed to young women (21-30 years) living in Belgium via a digital link.
Rheumatol Int
January 2025
Pharmacy, Radboudumc, Nijmegen, NL, Netherlands.
This study investigated severity, course and patterns of fatigue surrounding subcutaneous biological disease-modifying antirheumatic drug (bDMARD) injection in inflammatory rheumatic disease (IRD) patients using ecological momentary assessments and investigated self-reported adverse drug reactions (ADRs). In this prospective cohort study, IRD patients completed fatigue severity numeric rating scales (0-10) in web-based ecological momentary assessments in three waves of five days surrounding bDMARD injection. The course of fatigue was measured by the change in fatigue from pre-dosing to post-dosing scores and was classified as: worsening, improving or no clinically relevant change.
View Article and Find Full Text PDFArch Orthop Trauma Surg
January 2025
Department of Orthopaedics and Trauma, Medical University of Graz, Auenbruggerplatz 5, 8036, Graz, Austria.
Introduction: Liquid biopsy as a non-invasive method to investigate cancer biology and monitor residual disease has gained significance in clinical practice over the years. Whilst its applicability in carcinomas is well established, the low incidence and heterogeneity of bone and soft tissue sarcomas explains the less well-established knowledge considering liquid biopsy in these highly malignant mesenchymal neoplasms.
Materials And Methods: A systematic literature review adhering to the PRISMA guidelines initially identified 920 studies, of whom 68 original articles could be finally included, all dealing with clinical applicability of liquid biopsy in sarcoma.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!